ArticlePloS one2026
Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant melanoma (MM) is an emerging public health concern in East Asia's rapidly aging population. This study assessed the burden of MM among older adults aged ≥60 years from 1990 to 2023 and projected age-standardized rates to 2040.
methodsUsing GBD 2023 data, temporal trends were evaluated using Joinpoint regression and age-period-cohort analysis, together with age-, sex-, and location-specific comparisons. Future trends were projected using a multi-model forecasting framework incorporating ARIMA-derived temporal features. Seven candidate models were compared for each location-indicator combination. Historical data were chronologically divided into an 80% training set (1990-2016) and a 20% independent testing set (2017-2023), with model selection performed using five-fold rolling time-series cross-validation within the training set. Prediction intervals were generated using residual bootstrap.
resultsFrom 1990 to 2023, MM-related deaths among older adults in East Asia increased from 3,417.59 to 7,476.55, while DALYs increased from 116,499.14 to 196,356.14. Joinpoint analysis showed significant overall increases in ASIR and ASPR, whereas ASMR and ASDR exhibited only small, non-significant overall changes. This divergence is consistent with an important contribution from population aging and growth of the older population to the increasing absolute burden. Women generally had higher incidence and prevalence rates, whereas men had higher mortality and DALY rates. Projections to 2040 showed substantial variation across locations, with mortality and DALY rates expected to reach a plateau in several locations.
conclusionThe increasing MM burden and distinct sex and regional patterns require targeted early-detection strategies and equitable access to dermatological care. Future studies should use regional, subtype-specific cancer registries to evaluate ALM-specific burden and inform prevention strategies for East Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.